OOIR: Observatory of International Research

Papers

(The TQCC of Seminars in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
KRAS mutation in pancreatic cancer	141
Axillary surgery in breast cancer: An updated historical perspective	64
Implications of reactive oxygen species on cancer formation and its treatment	47
Chemotherapy-induced peripheral neuropathy and rehabilitation: A review	38
Cancer diagnosis in Brazil in the COVID-19 era	34
Homologous recombination repair deficiency as a therapeutic target in sarcoma	29
Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center	26
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature	17
Harnessing natural killer cells for the treatment of multiple myeloma	15
Radiation recall dermatitis: A review of the literature	14
Irreversible electroporation of locally advanced pancreatic cancer	13
Liquid Biopsy, the hype vs. hope in molecular and clinical oncology	13
The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options	13
Novel targeted therapies for advanced non-small lung cancer	13
A review of immune checkpoint blockade in breast cancer	12
Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China	12
Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management	12
Combination therapy in metastatic renal cell carcinoma: Back to the future?	12
Future directions in drug development in pancreatic cancer	11
Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview	10
Radiotherapy for locally advanced pancreatic ductal adenocarcinoma	10
The psychosocial and emotional experiences of cancer patients during the COVID-19 pandemic: A systematic review	9
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer	9
Pancreatic ductal adenocarcinoma in the era of precision medicine	9
Management problems in patients with pancreatic cancer from a surgeon's perspective	8

Barriers and facilitators to lung cancer screening and follow-up	8
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance	8
Non-pharmacologic interventions for improving cancer-related fatigue (CRF): A systematic review of systematic reviews and pooled meta-analysis	8
Neoadjuvant chemotherapy for gastric cancer. Has the time to decelerate the enthusiasm passed us by?	8
Epidemiology and genetics of early onset colorectal cancer—African overview with a focus on Ethiopia	7
Pathogenic signaling in multiple myeloma	7
Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias	7
Outcomes with panobinostat in heavily pretreated multiple myeloma patients	7
Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain	7
Comorbidity and life expectancy in shared decision making for lung cancer screening	6
Daratumumab: A review of current indications and future directions	6
Impact of CT screening in lung cancer: Scientific evidence and literature review	6
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review	6
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time	6
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics	6
Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far	6
The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma	6
Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies	6
Military exposures and lung cancer in United States Veterans	6
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in t	5
Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives	5
Treatment sequencing of metastatic colorectal cancer based on primary tumor location	5
The Impact of HIV on Non-AIDS defining gastrointestinal malignancies: A review	5
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans	5
Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrual	5
Is the neutrophil-to-lymphocyte ratio a prognostic factor in non-small cell lung cancer patients who receive adjuvant chemotherapy?	5
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects	5